Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.

The forward-looking statements in this press release involve significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from our current expectations. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. The analyses of clinical results of Riquent, previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and any other drug candidate that we may develop, including the results of any trials or models that are ongoing or that we may initiate in the future, could result in a finding that these drug candidates are not effective in large patient populations, do not provide a meaningful clinical benefit, or may reveal a potential safety issue requiring us to develop new candidates. The analysis of the data from our previous Phase 3 trial of Riquent showed that the trial did not reach statistical significance with respect to its primary endpoint, time to renal flare, or with respect to its secondary endpoint, time to treatment with high-dose corticosteroids or cyclophosphamide. The results from our clinical trials of Riquent, including the results of any trials that are ongoing or that we may initiate in the future, may not ultimately be sufficient to obtain regulatory clearance to market Riquent either in the United States or any other country, and we may be required to conduct additional clinical studies to demonstrate the safety and efficacy of Riquent in order to obtain marketing approval. There can be no assurance, however, that we will have the necessary resources to complete any current or future trials or that any such trials will sufficiently demonstrate the safety and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
(Date:8/29/2014)... -- According to a new market ... (SFE, Cold Pressed, Organic Solvent, & Others), and by ... & Others) - Global Trends & Forecast to ... Amaranth Seed Oil Market with an analysis and ... value. The Amaranth Seed Oil Market size in ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... March 30, 2011 MonoSol Rx, the developers ... specializing in proprietary pharmaceutical film products, today announced ... meeting with the U.S. Food and Drug Administration ... Soluble Film (OSF) under a 505(b)(2) pathway.  The ...
... 30, 2011 Cara Therapeutics, Inc. today announced the ... position of Chief Medical Officer.  In this role, Dr. ... lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid ... treatment of post-operative pain. "We are delighted ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 2Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 3
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip magazine ... keeps anxiety and panic attacks under control with a ... program review describes this new method as an ... panic attacks and overcome general anxiety related disorders. ... is the fact that it can be accessed by ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 RB SEO ... cost SEO service for small businesses. , RBSEO Services ... cannot afford costly search engine optimization service. So, the ... small businesses into account. , On being asked ... have introduced this low cost SEO service because many ...
(Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... , BOSTON, Oct. 16 Dr. Sanjay Gupta, CNN chief ... Hill Community College "Compelling Conversations" speaker series. ... in the A300 auditorium. , A leader in ... to the CNN television shows "American Morning" and "House Call ...
... The European Society of Cardiology wishes to comment on ... authorise the sale of cigarettes on the internet, to ... denies that this is the intention, the news is ... last year,s smoking ban. ESC spokesperson Professeur Ph.Gabriel ...
... WASHINGTON, October 16, 2009 MedImmune announced today it ... Pediatrics (AAP) 2009 National Conference & Exhibition that add ... burden of respiratory syncytial virus (RSV) on children, as ... influenza and RSV becoming more widespread this time of ...
... Area School District in Bradford County today became the ... influenza vaccine to its student population, the Department of ... all parents that immunizations play a significant role in ... affecting school-aged children, with almost two-thirds of all cases ...
... double the national average, researchers say , FRIDAY, Oct. 16 ... Milwaukee,s poorest neighborhoods smoke -- more than twice the national ... even while most of the households reported earning less than ... that a large number of these low-income smokers hold beliefs ...
... Oct. 16 More Vermont physicians will be using ... patient care, under a $1 million federal grant secured ... by Leahy and Vermont Information Technology Leaders, Inc. (VITL), ... adopt health information technology. , In June, Vermont was ...
Cached Medicine News:Health News:CNN Medical Correspondent Sanjay Gupta to Speak at Bunker Hill Community College 2Health News:ESC press statement : Cigarettes on sale on the internet 2Health News:ESC press statement : Cigarettes on sale on the internet 3Health News:MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 2Health News:MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 3Health News:Pennsylvania Department of Health Announces First School to Begin Administering H1N1 Vaccine to Students 2Health News:Smoking Keeps Its Grip on Urban Poor 2Health News:Smoking Keeps Its Grip on Urban Poor 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5
4.625 inches, curved blade 4 mm....
Walton foreign body gouge 4 1/2 inches, round end....
... made from MMA/VP material and has a high ... supplied with the base curve and total diameter ... available in a power range of -30.00DS to ... protective and therapeutic applications including the controlled on-eye ...
... premium high water content ... permeability. Standard one fit ... the following therapeutic conditions: ... bullous keratopathy, recurrent ulcers, ...
Medicine Products: